BRAF Kinase inhibitors are a class of targeted therapy drugs used for treating various cancers such as melanoma, colorectal cancer. They work by inhibiting the BRAF protein kinase, leading to decreased cancer cell growth and increased cancer cell death. The global BRAF Kinase Inhibitors Market is estimated to be valued at US$ 6 Billion in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031, as highlighted in a new report ... Read more
The BRAF kinase inhibitors market is primarily driven by the rising prevalence of cancers requiring targeted therapies. BRAF kinase inhibitors help in targeting tumors with mutated BRAF genes and are commonly used in cancers like melanoma, lung cancer, and colorectal cancer. BRAF inhibitors block the RAF/MEK/ERK pathway and prevent cell proliferation. They have significantly improved response rates and progression-free survival in BRAF-mutated cancers.
